Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Tough-to-Treat leukemia

NCT ID NCT03708003

Terminated Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a two-drug combination (ibrutinib and venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatments. The goal was to see if starting with ibrutinib alone, then adding venetoclax, could safely clear the disease from the body and allow some patients to take a break from medication. The trial was terminated early, but the approach aimed to reduce cancer cells to undetectable levels and lower the risk of side effects from treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia lymphoid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA LEUKEMIA RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

  • IOSI - Ospedale San Giovanni

    Bellinzona, 6501, Switzerland

  • Inselspital

    Bern, 3010, Switzerland

  • Kantonsspital Aarau

    Aarau, CH-5001, Switzerland

  • Kantonsspital Graubünden

    Chur, 7000, Switzerland

  • Kantonsspital Liestal

    Liestal, CH-4410, Switzerland

  • Kantonsspital Münsterlingen

    Münsterlingen, 8596, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • Luzerner Kantonsspital

    Lucerne, 6000, Switzerland

  • Spital STS AG Thun

    Thun, 3600, Switzerland

  • Universitätsspital Basel

    Basel, 4031, Switzerland

  • Universitätsspital Zürich

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.